COMMUNIQUÉS West-GlobeNewswire

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

24/10/2024 - 13:00

Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved lysosomal histopathology [...]

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

24/10/2024 - 13:00

– Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 – – Topline data anticipated in 2026 – WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT [...]

Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona

24/10/2024 - 13:00

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona LONDON – Oct. 24, 2024 – Avacta [...]

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

24/10/2024 - 13:00

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline [...]

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

24/10/2024 - 13:00

KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated dupilumab-like activity and was [...]

Epitopea Closes USD $31 million Pre-Series A Financing

24/10/2024 - 13:00

Proceeds support strategic development and clinical entry of lead Cryptigen immunotherapeutics CAMBRIDGE, United Kingdom and MONTREAL, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer [...]

Epitopea conclut des ententes de financement préalable à la série A d’un montant de 31 millions de dollars US

24/10/2024 - 13:00

Ces fonds vont soutenir le développement stratégique et l’entrée en phase clinique des immunothérapies de pointe Cryptigen CAMBRIDGE, Royaume-Uni et MONTRÉAL, 24 oct. 2024 (GLOBE NEWSWIRE) -- Epitopea, une société [...]

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

24/10/2024 - 13:00

WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today [...]

Auron Presents New Preclinical Data for Lead Program AUTX-703 Across Multiple Cancer Types

24/10/2024 - 13:00

Treatment with AUTX-703 resulted in notable cell differentiation and tumor growth inhibition in various primary cancer models AUTX-703 IND submission on track for late 2024 NEWTON, Mass. , Oct. 24, 2024 (GLOBE NEWSWIRE [...]

VSDHOne Expands to Offer Asynchronous Telehealth Treatments Including Skincare, Hair Loss, and Sexual Health

24/10/2024 - 13:00

VANCOUVER, British Columbia and LAS VEGAS, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing mobile clinical network [...]

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

24/10/2024 - 13:00

WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]

Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024

24/10/2024 - 13:00

ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that [...]

XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024

24/10/2024 - 13:00

● Health consequences of chronically high uric acid and xanthine oxidase in polycystic kidney disease in rats, mice and humans ● CALGARY, Alberta, Oct. 24, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or [...]

ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024

24/10/2024 - 12:50

Two poster presentations demonstrate ANI’s commitment to research in membranous nephropathy care PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today [...]

Tessera Therapeutics Presents New Preclinical Data in In Vivo AATD and SCD Programs at the 31st Annual Congress of the European Society of Gene and Cell Therapy

24/10/2024 - 12:30

A single intravenous administration of Gene Writer™ resulted in an estimated 79% hepatocyte genomic editing with an average of 84% of mRNA transcripts containing the edited sequence in non-human primates (NHPs) at the [...]

Le Patient Flow & Capacity Command Centre du KFSHRC : un modèle de gestion des soins intelligente

24/10/2024 - 12:04

Prévision de la demande en matière de soins de santé RIYAD, Arabie Saoudite, 24 oct. 2024 (GLOBE NEWSWIRE) -- Les établissements médicaux de classe mondiale s’efforcent de trouver des innovations durables dans le [...]

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

24/10/2024 - 12:00

BOSTON and LONDON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals , Inc. (Nasdaq: RYTM) and Axovia Therapeutics Ltd . today announced a joint research collaboration designed to advance the understanding of [...]

ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments

24/10/2024 - 11:00

Neufahrn / Garching / Munich, Germany, October 24, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM University Hospital [...]

Vistin Pharma ASA: Invitation to Q3 2024 conference call

24/10/2024 - 10:00

Oslo, Norway, 24 October 2024 Vistin Pharma ASA will release its third quarter and YTD 2024 results on Thursday 31st of October 2024. Vistin Pharma will host a conference call for all shareholders and interested parties [...]